In previous studies, we demonstrated that miR-193b expression is reduced in melanoma relative to benign nevi, and also that miR193b represses cyclin D1 and Mcl-1 expression. We suggested that stathmin 1 (STMN1) might be a target of miR-193b. STMN1 normally regulates microtubule dynamics either by sequestering free tubulin heterodimers or by promoting microtubule catastrophe. Increased expression of STMN1 has been observed in a variety of human malignancies, but its association with melanoma is unknown. We now report that STMN1 is upregulated during the progression of melanoma relative to benign nevi, and that STMN1 is directly regulated by miR-193b. Using an experimental cell culture approach, overexpression of miR-193b using synthetic microRNAs repressed STMN1 expression, whereas inhibition of miR-193b with anti-miR oligos increased STMN1 expression in melanoma cells. The use of a luciferase reporter assay confirmed that miR-193b directly regulates STMN1 by targeting the 3 0 -untranslated region of STMN1 mRNA. We further demonstrated that STMN1 is overexpressed in malignant melanoma compared with nevi in two independent melanoma cohorts, and that its level is inversely correlated with miR-193b expression. However, STMN1 expression was not significantly associated with patient survival, Breslow depth, mitotic count or patient age. STMN1 knockdown by small-interfering RNA in melanoma cells drastically repressed cell proliferation and migration potential, whereas ectopic expression of STMN1 using lentivirus increased cell proliferation and migration rates. Subsequent gene expression analysis indicated that interconnected cytoskeletal networks are directly affected following STMN1 knockdown. In addition, we identified deregulated genes associated with proliferation and migration, and revealed that p21
INTRODUCTION
Melanoma is the most dangerous form of skin cancer, and the incidence of melanoma has increased steadily over the past two decades. 1 Melanoma arises from melanocytes, and the progression of the disease has been associated with genetic and epigenetic changes, 2 some of which are now identified. For example, cyclin-dependent kinase inhibitor 2A (CDKN2A), a tumor suppressor gene, is often mutated in familial melanoma. 3 BRAF mutations are presented in B50% of melanoma cases while another B15% of tumors contain NRAS mutations, leading to a constitutively activated MAPK pathway. 3, 4 Recent studies have begun to unveil the important roles of microRNA (miRNA) dysregulation during the progression of melanoma. miRNAs are B22 nt single-stranded non-coding RNAs that post-transcriptionally regulate gene expression through binding to the 3 0 -untranslated region (UTR) of target mRNAs, subsequently leading to mRNA destabilization and translation inhibition. 5 More than 1000 miRNAs have been identified in the human genome (http://www.mirbase.org/cgi-bin/mirna_ summary.pl?org=hsa). A single miRNA can affect the expression of hundreds of genes, 6, 7 and 460% of human protein-coding genes are now predicted to be regulated by miRNAs. 8 miRNAs are involved in regulating virtually every aspect of cellular function, and are implicated in human diseases. 9 Mounting evidence indicates that miRNAs can function as oncogenes or tumor suppressor genes. 10 Aberrant expression of miRNAs has been reported in most human malignancies, 11 including melanoma. 12, 13 The dysregulation of specific miRNAs and their potential targets has been examined in melanoma, and begins to provide a clearer picture of cellular processes that are impacted by changes in miRNA expression. For example, miR-182 is reported to be upregulated in metastatic melanoma relative to nevi, and in vitro overexpression of miR-182 in melanoma cells promotes migration and survival by directly repressing microphthalmiaassociated transcription factor-M and FOXO3. 14 In contrast, miR-211, often downregulated or absent in melanoma, normally decreases migration and invasion capacity of cells by suppressing IGF2R, TGFBR2, NFAT5 and POU3F2. 15, 16 In our previous studies, miR-193b was identified as a significantly downregulated molecule in malignant melanoma. 12, 17 We demonstrated that miR-193b directly regulates cyclin D1 and Mcl-1. This tumor suppressor potential of miR-193b has been also reported in breast cancer, prostate cancer and hepatocellular carcinoma. [18] [19] [20] [21] The direct relationship between miRNAs and their target mRNAs provides a useful paradigm for studying disease progression. By examining downstream changes following disruption of expression of a particular miRNA, key target genes can be identified and their role in the process under study can be further investigated. Using this approach, we report that stathmin 1 (STMN1) is a direct target of miR-193b, and further, that this protein is overexpressed in melanoma. Reduction of STMN1 levels decreases the melanoma cell's ability to proliferate and migrate, whereas ectopic expression of STMN1 promotes the opposite effects.
RESULTS AND DISCUSSION miR-193b directly regulates STMN1 Because of our earlier studies suggesting that miR-193b was downregulated in melanoma relative to benign nevi, we had undertaken gene expression profiling in melanoma cell lines to identify potential targets of miR-193b. 12 From the list of genes showing reduced mRNA expression following ectopic expression of miR-193b, we selected candidates of interest, based on their known biological functions. One such gene of interest was STMN1. STMN1 is an important protein that regulates microtubule dynamics through either sequestering free tubulin heterodimers or promoting rapid microtubule depolymerization and shrinkage (catastrophe). 22 Overexpression of STMN1 has been observed in a variety of human malignancies, including breast cancer, prostate cancer, sarcoma, non-small cell lung cancer, hepatoma, gastric cancer and colorectal cancer. [23] [24] [25] [26] [27] [28] [29] [30] However, its association with melanoma is unknown.
To confirm the role of miR-193b in regulating STMN1, human melanoma cell lines were transfected with synthetic miR-193b or negative control oligonucleotides. We have previously demonstrated increased levels of miR-193b in melanoma cells transfected with synthetic miR-193b oligos using northern blotting and realtime PCR. 12, 17 Ectopic expression of miR-193b was associated with notably decreased STMN1 levels in all five melanoma cell lines tested by western blotting (Figure 1a ). We were interested to know whether reducing endogenous miR-193b levels would achieve the opposite effect and increase STMN1 protein levels. To answer this question, chemically modified, single-stranded oligonucleotides were used to inhibit endogenous miR-193 in Malme-3M, A375 and SK-MEL-2 cells, the cell lines expressing . Renilla luciferase activity was measured 24 h after transfection using the Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA). Data were normalized to firefly luciferase. Data shown are the mean ± s.e.m. from three independent experiments, each performed in triplicate. *Po0.05 were calculated using the independent samples t-test (IBM SPSS, Armonk, NY, USA).
relatively low levels of endogenous STMN1 among tested cell lines. As expected, decreasing miR-193b expression resulted in STMN1 levels increasing by 1.7, 1.4 and 1.3 folds, respectively ( Figure 1b) . These results suggest that miR-193b is involved in the regulation of STMN1.
Early experimental data showed that most metazoan miRNA target sites have perfect Watson-Crick base pairing with the miRNA 'seed', a 5 0 region of the miRNA centered on nucleotides 2-7.
31 TargetScan (www.targetscan.org) is a predictive algorithm developed to predict miRNA targets based on this concept of stringent miRNA seed binding and evolutionary conservation of target site. 32, 33 The STMN1 3 0 -UTR harbors two conserved miRNA-binding sites predicted by TargetScan. miR-193b/a, two miRNAs that contain the same miRNA 'seed,' are predicted to bind to nucleotides 58-64 of the STMN1 3 0 -UTR, while miR-101 is predicted to bind to nucleotides 284-290 (Figure 1c ). Of these three miRNAs, miR-193b is the only one that appears significantly dysregulated in melanoma. 12 To determine whether STMN1 is a direct or indirect target of miR-193b, we constructed two luciferase reporter plasmids: one wild-type vector cloned with a full length 3 0 -UTR of STMN1 and the other mutant vector cloned with the 3 0 -UTR containing a deletion at the miR-193b seed-binding site (Figure 1d) . A B70% decrease in luciferase activity was observed when the wild-type vector was TMA. This TMA includes 27 nevi, 53 primary melanoma and 40 metastatic melanoma. *Po0.05 and ***Po0.001 were calculated using the independent samples t-test. (e) Kaplan-Meier analysis comparing survival between patients with median and above (X6.7) vs below median (o6.7) of STMN expression. Fifty-three primary melanoma patients from the second cohort with average 5.6 years of follow-up were included in this analysis. P value was calculated from the log-rank test. The analysis was performed using SAS version 9.2 (SAS Inc., Cary, NC, USA).
cotransfected with miR-193b relative to the negative control. The repressive effect of miR-193b was relieved when cells were cotransfected with mutant vector (Figure 1e ). These results suggest that miR-193b post-transcriptionally regulates STMN1 expression through direct interaction with the predicted seed-binding site.
STMN1 is upregulated in Melanoma
We examined STMN1 expression directly in a series of melanoma tumor samples. A tissue microarray (TMA) was assembled, including eight nevi, six primary melanoma and eight metastatic melanoma samples. The rationale for using nevi as a benign comparator has been discussed previously. 17 Following immunohistochemical staining with a mouse mononclonal antibody against STMN1, the TMA slide was scanned to generate digital images (Figure 2a) . The staining intensities were assessed using the Aperio ImageScope (Aperio Technologies, Vista, CA, USA). The average STMN1 staining intensity was increased from 1.3% in nevi to 12.8% in primary melanoma to 26.5% in metastatic melanoma (Figure 2b) .
We subsequently compared STMN1 expression to miR-193b expression in the same 22 samples used to assemble the TMA described above (Figure 2b ). miR-193b expression levels were obtained from previous microarray studies. 12, 17 There was a significant inverse correlation (Pearson's coefficient r ¼ À 0.43, Po0.05) between STMN1 staining intensity and miR-193b expression (Figure 2c) . Despite the small sample size, our data demonstrate that STMN1 is upregulated during the progression of melanoma, and suggest the elevated level of STMN1 may be in part associated with the downregulation of miR-193b.
To validate the above results, a large independent TMA was constructed. The second TMA was composed of 27 nevi, 53 primary melanoma and 40 metastatic melanoma, none of which were used in the first TMA. STMN1 levels were significantly increased in primary melanoma (10.5%) and metastatic melanoma (18.4%) compared with nevi (0.4%) (Po0.001) in the second cohort (Figure 2d) . The difference in expression levels between primary and metastatic melanoma also reached significance (Po0.05). Our data confirm that STMN1 expression is significantly upregulated in malignant melanoma compared with nevi.
We found no significant association between STMN1 expression and patient survival. Kaplan-Meier analysis demonstrated that overall survival was not different in 53 primary melanoma patients with high (median and above) compared with low (below median) STMN1 expression (P ¼ 0.96) (Figure 2e ). Additionally, STMN1 expression was not significantly correlated with Breslow depth (P ¼ 0.78), mitotic count (P ¼ 0.95) or patient age (P ¼ 0.92) using Spearman's ranking test. Interestingly, the average expression of STMN1 was twice as high in males (mean ¼ 13.1) compared to females (mean ¼ 6.5) (P ¼ 0.0022, Wilcoxon Rank-sum test), confidence interval: 0.943-1.283, P ¼ 0.23). The reliability, sensitivity and power of the estimates from our study could be limited because of the relatively small sample size. Nevertheless, important genes in melanoma pathogenesis are not necessarily ideal prognostic markers. For example, studies have shown that BRAF and NRAS mutation status, cytoplasmic phospho-AKT expression and PTEN expression levels do not correlate with overall survival of melanoma patients. [34] [35] [36] Further studies are required to understand the link, if any, between STMN1 expression and patient survival.
The roles of STMN1 as an oncogene in melanoma STMN1 is a key factor in controlling microtubule dynamics, which is critical to cellular processes such as cell motility and cell division during mitosis. 23 To investigate the biological effect of STMN1 in melanoma, we decided first to reduce expression of STMN1 using small-interfering RNA (siRNA) in an in vitro cell line model. Malme-3M and A375 cells, two melanoma cell lines, were transfected with either negative control or STMN1 siRNA. As shown in Figure 3a , STMN1 levels were greatly decreased in cells transfected with STMN1 siRNA. Using the BrdU incorporation assay from Roche (Laval, Qué bec, Canada), we detected a significantly decreased proliferation rate in cells treated with STMN1 siRNA relative to cells treated with negative control (Figure 3b) . We next examined cell motility using a transwell migration assay. Reduction of STMN1 expression notably reduced the migration potential of melanoma cells by B85% in Malme-3M and B50% in A375 cells (Figure 3c ). Therefore, reducing STMN1 expression significantly hampered the proliferation and migration potential of melanoma cells. To test whether ectopic overexpression of STMN1 would achieve the opposite effects, we subsequently expressed STMN1 in Malme-3M cells using a hemagglutinin (HA)-tagged STMN1 construct in a lentiviral system. The western blot analysis confirmed increased expression of STMN1 following infection, showing the HA-tagged STMN1 protein migrating slightly slower than the endogenous protein ( Figure 3d ). As anticipated, ectopic expression of STMN1 significantly increased the cell proliferation rate in Malme-3M cells by B30% (Figure 3e ) and migration by B60% (Figure 3f) . Previous studies have shown miR-193b could repress cell proliferation and migration. 12, 18, 21 Ectopic expression of STMN1 could partially relieve the repressive effects of miR-193b on proliferation and migration (Supplementary Figure S1) , indicating miR-193b functions at least in part through suppressing the expression of STMN1. These results confirmed that STMN1 promotes cell proliferation and migration, and suggests overexpression of STMN1 could have an oncogenic role during progression of melanoma.
The microtubule destabilization mechanism of STMN1 has been well studied. STMN1 can either sequester tubulin dimers through its C-terminal region or promote microtubule catastrophe through its N-terminal region, depending on cellular pH. 37 STMN1 contains four phosphorylation sites: Ser 16, Ser 25, Ser 38 and Ser 63. In response to extracellular signals or during mitosis, 38 phosphorylation at one or more of the serine sites can weaken the tubulin-binding ability of STMN1 and increase free tubulin concentrations for microtubule assembly. 39 At the leading edge of migrating cells, Rac1 can activate PAK1, which phosphorylates STMN1 at Ser 16 and promotes localized microtubule growth. 40 During mitosis, cyclin-dependent kinases, CDK1 and CDK2, can phosphorylate STMN1 at Ser 25 and Ser 38.
However, the pathways downstream of STMN1-mediated microtubule destabilization are poorly understood. Therefore, we performed a gene expression analysis to globally screen genes and pathways affected by STMN1 knockdown. By comparing the transcriptome of Malme-3M cells transfected with STMN1 siRNA to cells transfected with control siRNA, we identified 272 differentially expressed genes, including 170 downregulated and 102 upregulated genes (Supplementary Table 2 ). Not surprisingly, STMN1 was one of the most downregulated genes, showing a 10.87-fold decrease in expression. Through pathway analysis of the set of differentially expressed genes, 25 downregulated and 6 upregulated genes were categorized into functions affecting cell cycle progression and/or migration (Table 1) . Integrin, actin, tight junction, Rac and Cdc42 signaling pathways were among the top canonical pathways associated with downregulated genes (Supplementary Table 3 Cip1/Waf1 and p27 Kip levels were elevated on western blots following STMN1 knockdown (Figure 3g ). Our exploratory study suggested that cyclin-dependent kinase inhibitors could be important downstream effectors of STMN1 signaling. Further investigation is needed to examine the relationship between STMN1 and those differentially expressed genes, and whether STMN1 could form protein complexes that directly affect cell proliferation and migration.
In summary, our study suggests STMN1 behaves as an oncogene in melanoma, in keeping with data from other cancers. Malme-3M cells and 3 Â 10 4 A375 cells were plated into the top chamber of 24-well insert (pore size 8 mm; BD Biosciences, Bedford, MA, USA) with RPMI medium after transfection. 10% fetal bovine serum was added in RPMI medium used as a chemoattractant in the lower chamber. Incubated for 16 h, cells that did not migrate through the pores were removed by a cotton swab. Cells on the lower side of membrane were fixed with 10% neutral buffered formalin, stained with 1% crystal violet and counted. Representative data from one of three independent experiments were shown as mean±s.e.m. (d) Ectopic expression of STMN1. Malme-3M cells were infected with lentivirus, stably expressing either WPI lentiviral vector (WPI control) or WPI lentiviral vector with HA-tagged STMN1 (STMN1-HA). The detailed lentiviral vector construction was described in Supplementary methods. The expression of STMN1 was examined by western blotting. (e, f ) Proliferation and migration effects in Malme-3M cells overexpressing STMN1. The procedures were described in (b) and (c). ***Po0.001 were calculated using the independent samples t-test. (g) p21
Cip1/Waf1 and p27
We demonstrated that miR-193b directly regulated STMN1 expression, and that upregulation of STMN1 may be at least in part due to reduced expression of miR-193b in malignant melanoma. Inhibition of STMN1 significantly repressed cell proliferation and migration, making it a potential therapeutic target in melanoma.
